Telix (TLX) CFO details PSAR and share rights holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Telix Pharmaceuticals Ltd Group Chief Financial Officer Darren Charlton Smith has filed an initial ownership report showing a mix of ordinary shares and equity awards. He holds 10,810 Ordinary Shares directly. He also holds Performance Share Appreciation Rights over 45,449 and 32,463 Ordinary Shares at an exercise price of 6.1500 (Australian Dollars) expiring on October 24, 2027, and over 88,497 Ordinary Shares at an exercise price of 6.9000 expiring on December 31, 2027. In addition, he holds Share Rights over 1,111 Ordinary Shares expiring March 31, 2028 and 14,741 Ordinary Shares expiring March 31, 2029. Footnotes state that the PSARs and certain Share Rights were granted between October 2022 and March 2026 and became, or will become, vested and exercisable based on continued service and testing after the audited calendar year 2026 financial results.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Smith Darren Charlton
Role
Group Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Performance Share Appreciation Rights (right to buy) | -- | -- | -- |
| holding | Performance Share Appreciation Rights (right to buy) | -- | -- | -- |
| holding | Performance Share Appreciation Rights (right to buy) | -- | -- | -- |
| holding | Share Rights | -- | -- | -- |
| holding | Share Rights | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Performance Share Appreciation Rights (right to buy) — 45,449 shares (Direct);
Share Rights — 1,111 shares (Direct);
Ordinary Shares — 10,810 shares (Direct)
Footnotes (1)
- The performance share appreciation rights (PSARs) were granted on October 24, 2022, and became vested and exercisable on March 6, 2025. Conversion price is reported in Australian Dollars. The PSARs were granted on October 24, 2022 and became vested and exercisable on March 6, 2025. The PSARs were granted on April 25, 2023 and became vested and exercisable on March 12, 2026. The share rights (SRs) were granted on January 1, 2025 and became vested and exercisable on March 5, 2026. The SRs were granted on March 18, 2026 and will become vested and exercisable in approximately February or March 2027. The SRs are subject to forfeiture where employment is terminated for cause only, subject to continued service with the issuer. The vesting date will be communicated to the reporting person following testing that will occur after the audited calendar year 2026 financial results announcement. Each SR represents the contingent right to receive one ordinary share.
Key Figures
Ordinary Shares held: 10,810 shares
PSARs at 6.1500 (tranche 1): 45,449 underlying shares
PSARs at 6.1500 (tranche 2): 32,463 underlying shares
+3 more
6 metrics
Ordinary Shares held
10,810 shares
Direct holdings reported on Form 3
PSARs at 6.1500 (tranche 1)
45,449 underlying shares
Exercise price 6.1500, expiration October 24, 2027, direct
PSARs at 6.1500 (tranche 2)
32,463 underlying shares
Exercise price 6.1500, expiration October 24, 2027, direct
PSARs at 6.9000
88,497 underlying shares
Exercise price 6.9000, expiration December 31, 2027, direct
Share Rights 2028
1,111 underlying shares
Exercise price 0.0000, expiration March 31, 2028, direct
Share Rights 2029
14,741 underlying shares
Exercise price 0.0000, expiration March 31, 2029, direct
Key Terms
Performance Share Appreciation Rights, Share Rights, vested and exercisable, conversion price, +1 more
5 terms
vested and exercisable financial
"became vested and exercisable on March 6, 2025"
conversion price financial
"Conversion price is reported in Australian Dollars."
The conversion price is the fixed price at which a convertible security, like a bond or preferred stock, can be exchanged for shares of common stock. It acts like a set rate that determines how many shares an investor can receive if they choose to convert their investment. This helps investors understand the value and potential benefits of converting their securities into company shares.
contingent right financial
"Each SR represents the contingent right to receive one ordinary share."
FAQ
What does Telix Pharmaceuticals (TLX) CFO Darren Smith report in this Form 3?
Telix Pharmaceuticals CFO Darren Smith reports initial holdings of 10,810 ordinary shares, plus several tranches of Performance Share Appreciation Rights and Share Rights that can convert into ordinary shares if vesting and exercise conditions are met over the coming years.
Are Telix (TLX) CFO Darren Smith’s equity awards subject to forfeiture conditions?
The Share Rights granted March 18, 2026 are subject to forfeiture if employment is terminated for cause, and vesting depends on continued service and testing after audited calendar year 2026 financial results, according to the disclosed footnote language.